BioXcel Therapeutics Inc logo

BTAI - BioXcel Therapeutics Inc Share Price

$42.54 -0.4  -1.0%

Last Trade - 5:09pm

Mid Cap
Market Cap ÂŁ753.5m
Enterprise Value ÂŁ585.5m
Revenue ÂŁn/a
Position in Universe 2732nd / 6647
Unlock BTAI Revenue
Relative Strength (%)
1m -15.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -39.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BioXcelTherapeutics Inc revenues was not reported. Net lossincreased from $24.7M to $61.1M. Higher net loss reflectsResearch and development increase from $19.3M to $46.6M(expense), General and administrative increase from $5.9Mto $14.6M (expense), Dividend and interest income, netdecrease of 76% to $121K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BTAI
Graphical History


BTAI Revenue Unlock BTAI Revenue

Net Income

BTAI Net Income Unlock BTAI Revenue

Normalised EPS

BTAI Normalised EPS Unlock BTAI Revenue

PE Ratio Range

BTAI PE Ratio Range Unlock BTAI Revenue

Dividend Yield Range

BTAI Dividend Yield Range Unlock BTAI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BTAI EPS Forecasts Unlock BTAI Revenue
Profile Summary

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 29, 2017
Public Since March 8, 2018
No. of Shareholders: 11
No. of Employees: 40
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 24,368,357
Free Float (0.0%)
Eligible for
BTAI Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BTAI
Upcoming Events for BTAI
Thursday 20th May, 2021 Estimate
BioXcel Therapeutics Inc Annual Shareholders Meeting
Frequently Asked Questions for BioXcel Therapeutics Inc
What is the BioXcel Therapeutics Inc share price?

As of 5:09pm, shares in BioXcel Therapeutics Inc are trading at $42.54, giving the company a market capitalisation of ÂŁ753.5m. This share price information is delayed by 15 minutes.

How has the BioXcel Therapeutics Inc share price performed this year?

Shares in BioXcel Therapeutics Inc are currently trading at $42.54 and the price has moved by 43.39% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioXcel Therapeutics Inc price has moved by 13.52% over the past year.

What are the analyst and broker recommendations for BioXcel Therapeutics Inc?

Of the analysts with advisory recommendations for BioXcel Therapeutics Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioXcel Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioXcel Therapeutics Inc next release its financial results?

BioXcel Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BioXcel Therapeutics Inc dividend yield?

BioXcel Therapeutics Inc does not currently pay a dividend.

Does BioXcel Therapeutics Inc pay a dividend?

BioXcel Therapeutics Inc does not currently pay a dividend.

When does BioXcel Therapeutics Inc next pay dividends?

BioXcel Therapeutics Inc does not currently pay a dividend.

How do I buy BioXcel Therapeutics Inc shares?

To buy shares in BioXcel Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioXcel Therapeutics Inc?

Shares in BioXcel Therapeutics Inc are currently trading at $42.54, giving the company a market capitalisation of ÂŁ753.5m.

Where are BioXcel Therapeutics Inc shares listed? Where are BioXcel Therapeutics Inc shares listed?

Here are the trading details for BioXcel Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BTAI
What kind of share is BioXcel Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, BioXcel Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioXcel Therapeutics Inc share price forecast 2021?

Shares in BioXcel Therapeutics Inc are currently priced at $42.54. At that level they are trading at 0.158% discount to the analyst consensus target price of 0.00.

Analysts covering BioXcel Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.86 for the next financial year.

How can I tell whether the BioXcel Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioXcel Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -8.71%. At the current price of $42.54, shares in BioXcel Therapeutics Inc are trading at -12.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioXcel Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for BioXcel Therapeutics Inc.

Who are the key directors of BioXcel Therapeutics Inc?

BioXcel Therapeutics Inc's management team is headed by:

Vimal Mehta - PRE
Vincent O'Neill - OTH
Richard Steinhart - CFO
Frank Yocca - CSO
Peter Mueller - CHM
Sandeep Laumas - IND
Krishnan Nandabalan - CFD
Michal Votruba - IND
Will Kane - EVP
Reina Benabou - SVP
Javier Rodriguez - SVP
June Bray - DRC
Who are the major shareholders of BioXcel Therapeutics Inc?

Here are the top five shareholders of BioXcel Therapeutics Inc based on the size of their shareholding:

Bioxcel Corp Corporation
Percentage owned: 37.02% (9.02m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 8.19% (2.00m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 6.87% (1.67m shares)
SPDR S&P Biotech ETF Mutual Fund
Percentage owned: 6.09% (1.48m shares)
Artemis Investment Management LLP Investment Advisor/Hedge Fund
Percentage owned: 4.16% (1.01m shares)
Similar to BTAI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.